Gee tell that to the families in the trial who have "begged" that their loved ones have continued access to 2-73 because of their cognitive improvement. I think you should get into this trial too---you clearly have cognitive impairment!!!
I wish your mom all the best---
I sincerely hope this turns out to be a god send to all those families who care for loved ones suffering from this cruel disease---but I also don't want to see hopes "dashed" if this doesn't work out (as many other drugs have done before)
Biogen (BIIB) fell almost 23% on July 24---the results they reported at the AD conference were far from outstanding---if they feel that it would be better to go in a different direction--I think AVXL will be in their "cross hairs" if the trial results continue to be outstanding--then (as noted) Pfizer are losing their patent on Aricept so they would also be interested in acquiring a company like AVXL especially since Aricept is being combined with 2-73 in this current study--would give them a chance to resume this patent since the combo of drugs isn't the same as Aricept alone---let the "bidding war" begin
I believe that the interim CEO (Micheal Astrue) took a large part of his severance upon leaving the company in stock (obviously he was confident about the direction the company was going)--and this was before the pilot study had even started
I also read that they still haven't evaluated what the optimum dose of 2-73 is-this is something they hope to assess as the trial goes on---in other words there may be an even greater benefit when the optimum dose is ultimately achieved (benefit without major side effects)
Unless I misinterpreted something--I read that many of the family members of the patients participating in this trial have literally "begged" that their loved ones be allowed to stay on this drug/trial based on their cognitive improvement---if that isn't a positive sign I don't know what would be
even if the final study results aren't as spectacular---this drug has shown great results as a co-adjuvant in controlling epilepsy seizures--so it still has value
BIIB is down almost 26% today--if their AD drug fails (and the results presented this week weren't "earth shattering")--I'm sure they will be one of the many "suitors" for what ADXL offers
arecept is an established drug for AD---but does it help every person who takes it??? NO--if this drug helps even half the patients who are on it then it still is a step above what's out there now
AVXL continues to do well (despite today's lousy market)-up another 16%--I have been "long" NVIV from before Reynold's ouster---but this company may be another stock I'm going to retire on--their early results in an Alzeheimer's disease study have been remarkable to say the least
Press release (July 22) said "end of year"--will more tentative results be available in September?--have a feeling many of the bigger players (BIIB etc) are going to be watching these results with interest-you can be sure they won't remain on the "sidelines" very long if the results are as exempliary as July 22 early results were---after that "Let the bidding war begin"
own NVIV--incredible potential--developing a "polymer scaffold" for acute spinal cord injury--first three human patients have shown recovery of neurologic function (bladder/bowel and some motor/sensory function)---no competition and outstanding management team (including Dr. Robert Langer from MIT)
when did this disgusting tool of Jim Cramer's ever get any "respect"?? His continual bashing of MNKD is ridiculous (all of his claims about Afrezza have been discredited) as is his attacks on NWBO. I hope he is eventually taken before the SEC and jailed
Thanks so much (Mix.Jack)-for enlightening me on AVXL (have admired your comments on the NVIV board for a long time)---did my DD on AVXL and bought in (sold off AMBS to do so)----liked the fact they have a "pipeline" of drugs too--and even if today's results hadn't been "stellar" (which they were) this drug still has tremendous potential for epilepsy too--I have a substantial position in NVIV but am going to somehow find more funds to add to ADXL before the price rises too high (hoping some profit taking may make the price cheaper)
Thanks very much for your clarity on the poster session--obviously this poster will just be a possible "teaser" for the results that may follow in September-if their drug candidate does show changes in electrophysiological markers in AD than it would prove the drug does achieve "penetration" to the sites where it would be needed to make a meaningful difference in AD (if any)
I still want someone to explain to me why would AVXL be reporting anything 7/22 (since the trial won't be fully analyzed until September)-if the results weren't decent?--if they were lousy why would they even bother showing up? wouldn't the CEO hold off purchasing more shares or dump some of his current holdings?
I think things were moving too slow--I have no doubt on the future success of RNN (likely a takeover target)--too many promising things in the pipeline----will take this opportunity to buy more-the new COO will be hired to be more aggressive in getting RNN's potential to fruition
he's also the "clown" who said to hold "Bear Stearns" the day before it crashed 92% in 2008-then he tried to say he had been "misinterpreted"-both him and his minion Adam Feuerstein are crooks--I don't understand why he hasn't been shut down by the SEC
I held AMBS (another Alzeheimer disease focused company) and sold my position to get into AVXL--AMBS has an early diagnostic test for AD and a lot of early stage drugs but their CEO is very inexperienced and has not impressed me meeting any other their timelines---the CEO of AVXL seems more "on the ball" and has been accumulating more shares lately (not "huge" amounts but he already hold 4 million shares)--their current trial results aren't due until September but they are presenting a poster at a meeting 7/22 with preliminary results (figure must be good early news or why else would they present these results)
I agree--SA has been particularly guilty of attacking the inhaled insulin company MNKD-they published an article that was so bad (July 14) that they were forced to remove it due to "factual inaccuracies"